Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (240)	12/28/1998 1:26:00 AM
From: Steven Rachbach	Read Replies (1) \| Respond to of 1127

David, The typical causes of peripheral vascular disease are hypertension, high cholesterol levels, diabetes, smoking, and high triglyceride levels. The market is quite large although I don't have any figures at hand. Traditional treatment of symptomatic peripheral vascular disease has been several medications (which do not work very well) and surgery to place artificial bypass vessels. I am sure the generation of new blood vessels in the heart would be of possible great therapeutic importance in the treatment of coronary artery disease as well. Regards, Steve Rachbach